H. Asahina

N. Shinagawa, E. Kikuchi, H. Mizugaki, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Analysis of 27 Patients with Malignant Pleural Mesothelioma Treated at Our Institution

M. Nishimura, S. Oizumi, N. Katoh, 2015 .

Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study

Xiaojin Shi, T. Tamura, Yasuhide Yamada, 2013, Investigational New Drugs.

Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.

K. Kubota, T. Tamura, N. Yamamoto, 2012, Clinical lung cancer.

Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage

M. Nishimura, H. Goudarzi, N. Shinagawa, 2018, Internal medicine.

Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803

Kunihiko Kobayashi, M. Maemondo, T. Nukiwa, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension

S. Konno, N. Shinagawa, E. Kikuchi, 2022, BMC Pulmonary Medicine.

A Clinical Analysis of 10 Cases with Oligometastases of Non-small Cell Carcinoma

M. Nishimura, N. Shinagawa, E. Kikuchi, 2018, Haigan.

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

Koichi Yamazaki, Satoshi Morita, Masahiro Fukuoka, 2009, Clinical Cancer Research.

Endobronchial ultrasonography with a guide sheath in the diagnosis of benign peripheral diseases.

Y. Nasuhara, M. Nishimura, Y. Matsuno, 2012, The Annals of thoracic surgery.

Endobronchial ultrasonography with guide-sheath for peripheral pulmonary lesions

Y. Onodera, M. Nishimura, M. Imura, 2004, European Respiratory Journal.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Shohei Koyama, Robert E. Jones, Gordon J. Freeman, 2016, Nature Communications.

A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)

M. Nishimura, H. Dosaka-akita, T. Harada, 2018, International Journal of Clinical Oncology.

Establishment and characterization of amylase-producing lung adenocarcinoma cell line, IMEC-2.

M. Nishimura, H. Dosaka-akita, T. Itoh, 2005, Anticancer research.

Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.

P. Tamayo, R. Neve, Kwok-Kin Wong, 2018, Cancer cell.

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

Jing Wang, G. Freeman, I. Wistuba, 2016, Cancer research.

NSCLC Driven by DDR 2 Mutation Is Sensitive to Dasatinib and JQ 1 Combination Therapy

M. Meyerson, P. Hammerman, Kwok-Kin Wong, 2015 .

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors

M. Tanioka, T. Tamura, N. Yamamoto, 2011, Cancer Chemotherapy and Pharmacology.

Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.

M. Nishimura, H. Dosaka-akita, K. Yamazaki, 2006, Lung cancer.

Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803.

Kunihiko Kobayashi, M. Maemondo, T. Nukiwa, 2013 .

A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors *,†

M. Tanioka, Xiaojin Shi, T. Tamura, 2012, Cancer science.

CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.

Kwok-Kin Wong, F. Al-Shahrour, P. Janne, 2019, Cancer research.

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

M. Nishimura, H. Dosaka-akita, S. Oizumi, 2011, Oncology.

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

M. Nishimura, H. Dosaka-akita, S. Ogura, 2006, British Journal of Cancer.

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

M. Nishimura, M. Munakata, H. Dosaka-akita, 2007, BMC Cancer.

Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.

M. Nishimura, M. Munakata, H. Dosaka-akita, 2005, Anticancer research.

Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.

N. Shinagawa, E. Kikuchi, H. Mizugaki, 2019, Clinical lung cancer.

Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.

M. Seike, K. Sugio, Kunihiko Kobayashi, 2023, European journal of cancer.

Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors

H. Wakui, N. Yamazaki, Shigenobu Suzuki, 2015, Investigational New Drugs.

Innovator and generic cisplatin formulations: Comparison of renal toxicity

K. Kubota, T. Tamura, N. Yamamoto, 2011, Cancer science.

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

P. Ansell, M. Tanioka, T. Tamura, 2012, Cancer Chemotherapy and Pharmacology.

M. Nishimura, K. Yamazaki, S. Oizumi, 2007, Chest.

A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).

M. Nishimura, H. Dosaka-akita, T. Kojima, 2019, Lung cancer.

Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer.

M. Nishimura, H. Dosaka-akita, M. Imura, 2004, Japanese journal of clinical oncology.

Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer

Y. Ohe, Hitoshi Sato, Hiroshi Yamamoto, 2012, Cancer Chemotherapy and Pharmacology.

Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).

H. Dosaka-akita, F. Hommura, T. Harada, 2021, Lung cancer.

Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.

K. Sugio, Kunihiko Kobayashi, S. Oizumi, 2021, European journal of cancer.

A phase II study of gefitinib as a first-line therapy for advanced non-small cell lung cancers with epidermal growth factor receptor (EGFR) gene mutations.

M. Nishimura, H. Dosaka-akita, S. Ogura, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial.

H. Dosaka-akita, T. Harada, S. Oizumi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer

H. Dosaka-akita, F. Hommura, T. Harada, 2023, Cancer medicine.

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma

S. Konno, N. Shinagawa, E. Kikuchi, 2020, Respiratory medicine case reports.

Koichi Yamazaki, Kazuo Miyasaka, Yuya Onodera, 2007, Chest.

Transbronchial biopsy using endobronchial ultrasonography with a guide sheath and virtual bronchoscopic navigation.

Koichi Yamazaki, Yuya Onodera, Masaharu Nishimura, 2005, Chest.

Combining transbronchial biopsy using endobronchial ultrasonography with a guide sheath and positron emission tomography for the diagnosis of small peripheral pulmonary lesions.

M. Nishimura, N. Tamaki, S. Oizumi, 2010, Lung cancer.

Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine a trial.

N. Sunaga, Kunihiko Kobayashi, Satoshi Watanabe, 2023, Cancer science.

Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.

S. Oizumi, M. Maemondo, T. Nukiwa, 2014, Respiratory investigation.

Transbronchial Biopsy for Peripheral Pulmonary Lesions Under Real-time Endobronchial Ultrasonographic Guidance

M. Nishimura, S. Oizumi, N. Shinagawa, 2009, Journal of bronchology & interventional pulmonology.

Phase I and Pharmacokinetics/Pharmacodynamics (PK/PD) Study of RO5126766, a First-in-Class Dual Raf/Mek Inhibitor, in Japanese Patients with Advanced Solid Tumors

N. Yamazaki, T. Tamura, N. Yamamoto, 2012 .

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

Jing Wang, I. Wistuba, P. Hammerman, 2016, Cancer research.